Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
191 questions in 16 reviews · Sexually Transmitted Infections
current versionsNo studies 38 · 19.9%Ungraded 4 · 2.1%Very low 53 · 27.7%Low 68 · 35.6%Moderate 19 · 9.9%High 9 · 4.7%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Regimens containing quinolone vs regimens containing cephalosporins Fertility outcome · women with PID Antibiotic therapy for pelvic inflammatory disease (2020) · Cochrane | no estimate extracted | NR | No studies |
Regimens containing nitroimidazole vs no nitroimidazole Clinical cure according to criteria established by study authors Mild‐moderate PID · women with PID Antibiotic therapy for pelvic inflammatory disease (2020) · Cochrane | RR 1.02 [0.95, 1.09] | NR | Moderate |
Regimens containing nitroimidazole vs no nitroimidazole Clinical cure according to criteria established by study authors Mild‐moderate PID · women with PID Antibiotic therapy for pelvic inflammatory disease (2020) · Cochrane | RR 1.05 [1, 1.12] | NR | High |
Regimens containing nitroimidazole vs no nitroimidazole Clinical cure according to criteria established by study authors Severe PID · women with PID Antibiotic therapy for pelvic inflammatory disease (2020) · Cochrane | RR 0.96 [0.92, 1.01] | NR | Moderate |
Regimens containing nitroimidazole vs no nitroimidazole Adverse events: any antibiotic‐related adverse event leading to discontinuation of therapy · women with PID Antibiotic therapy for pelvic inflammatory disease (2020) · Cochrane | RR 1.05 [0.69, 1.61] | NR | Low |
Regimens containing macrolides (azithromycin) vs regimens containing tetracycline (doxycycline) Clinical cure according to criteria established by study author Mild‐moderate PID · women with PID Antibiotic therapy for pelvic inflammatory disease (2020) · Cochrane | RR 1.35 [1.1, 1.67] | NR | Moderate |
Regimens containing nitroimidazole vs no nitroimidazole Microbiological clearance · women with PID Antibiotic therapy for pelvic inflammatory disease (2020) · Cochrane | no estimate extracted | NR | No studies |
Regimens containing nitroimidazole vs no nitroimidazole Laparoscopic evidence of resolution of PID based on physician opinion · women with PID Antibiotic therapy for pelvic inflammatory disease (2020) · Cochrane | no estimate extracted | NR | No studies |
Regimens containing nitroimidazole vs no nitroimidazole Length of stay (for inpatient care) · women with PID Antibiotic therapy for pelvic inflammatory disease (2020) · Cochrane | no estimate extracted | NR | No studies |
Regimens containing nitroimidazole vs no nitroimidazole Fertility outcome · women with PID Antibiotic therapy for pelvic inflammatory disease (2020) · Cochrane | no estimate extracted | NR | No studies |
Regimens containing clindamycin plus aminoglycoside vs regimens containing quinolone Clinical cure according to criteria established by authors Mild‐moderate PID · women with PID Antibiotic therapy for pelvic inflammatory disease (2020) · Cochrane | RR 0.88 [0.69, 1.13] | NR | Very low |
Regimens containing clindamycin plus aminoglycoside vs regimens containing quinolone Clinical cure according to criteria established by authors Severe PID · women with PID Antibiotic therapy for pelvic inflammatory disease (2020) · Cochrane | RR 1.02 [0.87, 1.19] | NR | Low |
Regimens containing clindamycin plus aminoglycoside vs regimens containing quinolone Adverse events: any antibiotic‐related adverse event leading to discontinuation of therapy · women with PID Antibiotic therapy for pelvic inflammatory disease (2020) · Cochrane | RR 0.21 [0.02, 1.72] | NR | Very low |
Regimens containing clindamycin plus aminoglycoside vs regimens containing quinolone Microbiological clearance · women with PID Antibiotic therapy for pelvic inflammatory disease (2020) · Cochrane | RR 1.08 [0.85, 1.36] | NR | Very low |
Regimens containing clindamycin plus aminoglycoside vs regimens containing quinolone Laparoscopic evidence of resolution of PID based on physician opinion · women with PID Antibiotic therapy for pelvic inflammatory disease (2020) · Cochrane | no estimate extracted | NR | No studies |
Regimens containing clindamycin plus aminoglycoside vs regimens containing quinolone Length of stay (for inpatient care) · women with PID Antibiotic therapy for pelvic inflammatory disease (2020) · Cochrane | no estimate extracted | NR | No studies |
Regimens containing macrolides (azithromycin) vs regimens containing tetracycline (doxycycline) Clinical cure according to criteria established by study authors Severe PID · women with PID Antibiotic therapy for pelvic inflammatory disease (2020) · Cochrane | RR 1 [0.96, 1.05] | NR | Low |
Regimens containing clindamycin plus aminoglycoside vs regimens containing quinolone Fertility outcome · women with PID Antibiotic therapy for pelvic inflammatory disease (2020) · Cochrane | no estimate extracted | NR | No studies |
Regimens containing clindamycin plus aminoglycoside vs regimens containing cephalosporin Clinical cure according to criteria established by authors Mild‐moderate PID · women with PID Antibiotic therapy for pelvic inflammatory disease (2020) · Cochrane | RR 1.02 [0.95, 1.09] | NR | Low |
Regimens containing clindamycin plus aminoglycoside vs regimens containing cephalosporin Clinical cure according to criteria established by authors Severe PID · women with PID Antibiotic therapy for pelvic inflammatory disease (2020) · Cochrane | RR 1 [0.95, 1.06] | NR | Moderate |
Regimens containing clindamycin plus aminoglycoside vs regimens containing cephalosporin Adverse events: any antibiotic‐related adverse event leading to discontinuation of therapy · women with PID Antibiotic therapy for pelvic inflammatory disease (2020) · Cochrane | RR 0.78 [0.18, 3.42] | NR | Very low |
Regimens containing clindamycin plus aminoglycoside vs regimens containing cephalosporin Microbiological clearance · women with PID Antibiotic therapy for pelvic inflammatory disease (2020) · Cochrane | RR 1.02 [0.94, 1.1] | NR | Very low |
Regimens containing clindamycin plus aminoglycoside vs regimens containing cephalosporin Laparoscopic evidence of resolution of PID based on physician opinion · women with PID Antibiotic therapy for pelvic inflammatory disease (2020) · Cochrane | no estimate extracted | NR | No studies |
Regimens containing clindamycin plus aminoglycoside vs regimens containing cephalosporin Length of stay (for inpatient care) · women with PID Antibiotic therapy for pelvic inflammatory disease (2020) · Cochrane | no estimate extracted | NR | No studies |
Regimens containing clindamycin plus aminoglycoside vs regimens containing cephalosporin Fertility outcome · women with PID Antibiotic therapy for pelvic inflammatory disease (2020) · Cochrane | no estimate extracted | NR | No studies |
Regimens containing macrolides (azithromycin) vs regimens containing tetracycline (doxycycline) Adverse events: any antibiotic‐related adverse event leading to discontinuation of therapy · women with PID Antibiotic therapy for pelvic inflammatory disease (2020) · Cochrane | RR 0.71 [0.38, 1.34] | NR | Low |
Regimens containing macrolides (azithromycin) vs regimens containing tetracycline (doxycycline) Microbiological clearance · women with PID Antibiotic therapy for pelvic inflammatory disease (2020) · Cochrane | RR 1.02 [0.98, 1.06] | NR | Ungraded |
Regimens containing macrolides (azithromycin) vs regimens containing tetracycline (doxycycline) Laparoscopic evidence of resolution of PID based on physician opinion · women with PID Antibiotic therapy for pelvic inflammatory disease (2020) · Cochrane | no estimate extracted | NR | No studies |
Regimens containing macrolides (azithromycin) vs regimens containing tetracycline (doxycycline) Length of stay (for inpatient care) · women with PID Antibiotic therapy for pelvic inflammatory disease (2020) · Cochrane | no estimate extracted | NR | No studies |
Regimens containing macrolides (azithromycin) vs regimens containing tetracycline (doxycycline) Fertility outcome · women with PID Antibiotic therapy for pelvic inflammatory disease (2020) · Cochrane | no estimate extracted | NR | No studies |
Regimens containing quinolone vs regimens containing cephalosporins Clinical cure according to criteria established by study authors Mild‐moderate PID · women with PID Antibiotic therapy for pelvic inflammatory disease (2020) · Cochrane | RR 1.05 [0.98, 1.14] | NR | Low |
Azithromycin vs doxycycline Microbiological failure Men · men and non‐pregnant women with symptomatic (uterine cervicitis and urethritis), or asymptomatic genital CT infection,… Antibiotics for treating urogenital Chlamydia trachomatis infection in men and non‐pregnant women (2019) · Cochrane | RR 2.45 [1.36, 4.41] | 9 studies · 821 participants | Moderate |
Doxycycline vs quinolones Microbiological failure Women Doxycycline 100 mg twice a day for 7 days vs ofloxacin 400 mg once a day for 7 days · men and non‐pregnant women with symptomatic (uterine cervicitis and urethritis), or asymptomatic genital CT infection,… Antibiotics for treating urogenital Chlamydia trachomatis infection in men and non‐pregnant women (2019) · Cochrane | no estimate extracted | 1 study · 83 participants | Low |
Doxycycline vs quinolones Microbiological failure Men and women Doxycycline 100 mg twice a day for 7 days vs ofloxacin 300 mg once a day for 7 days · men and non‐pregnant women with symptomatic (uterine cervicitis and urethritis), or asymptomatic genital CT infection,… Antibiotics for treating urogenital Chlamydia trachomatis infection in men and non‐pregnant women (2019) · Cochrane | no estimate extracted | 1 study · 18 participants | Low |
Doxycycline vs quinolones Adverse events Men and women Assessed by participants' self‐report · men and non‐pregnant women with symptomatic (uterine cervicitis and urethritis), or asymptomatic genital CT infection,… Antibiotics for treating urogenital Chlamydia trachomatis infection in men and non‐pregnant women (2019) · Cochrane | RR 1.02 [0.66, 1.55] | 3 studies · 339 participants | Very low |
Doxycycline vs quinolones Clinical failure Men Doxycycline 100 mg twice a day for 7 days vs ofloxacin 400 mg once a day for 7 days · men and non‐pregnant women with symptomatic (uterine cervicitis and urethritis), or asymptomatic genital CT infection,… Antibiotics for treating urogenital Chlamydia trachomatis infection in men and non‐pregnant women (2019) · Cochrane | RR 0.85 [0.28, 2.62] | 1 study · 36 participants | Very low |
Doxycycline vs quinolones Clinical failure Women Doxycycline 100 mg twice a day for 7 days vs ofloxacin 400 mg once a day for 7 days. · men and non‐pregnant women with symptomatic (uterine cervicitis and urethritis), or asymptomatic genital CT infection,… Antibiotics for treating urogenital Chlamydia trachomatis infection in men and non‐pregnant women (2019) · Cochrane | RR 0.94 [0.39, 2.25] | 2 studies · 127 participants | Very low |
Doxycycline vs quinolones Clinical failure Men Doxycycline 100 mg twice a day for 7 days vs ofloxacin 300 mg once a day for 7 days · men and non‐pregnant women with symptomatic (uterine cervicitis and urethritis), or asymptomatic genital CT infection,… Antibiotics for treating urogenital Chlamydia trachomatis infection in men and non‐pregnant women (2019) · Cochrane | no estimate extracted | 1 study · 18 participants | Low |
Doxycycline vs quinolones Antimicrobial resistance · men and non‐pregnant women with symptomatic (uterine cervicitis and urethritis), or asymptomatic genital CT infection,… Antibiotics for treating urogenital Chlamydia trachomatis infection in men and non‐pregnant women (2019) · Cochrane | no estimate extracted | NR | No studies |
Doxycycline vs quinolones Reinfection · men and non‐pregnant women with symptomatic (uterine cervicitis and urethritis), or asymptomatic genital CT infection,… Antibiotics for treating urogenital Chlamydia trachomatis infection in men and non‐pregnant women (2019) · Cochrane | no estimate extracted | NR | No studies |
Azithromycin vs doxycycline Microbiological failure Women · men and non‐pregnant women with symptomatic (uterine cervicitis and urethritis), or asymptomatic genital CT infection,… Antibiotics for treating urogenital Chlamydia trachomatis infection in men and non‐pregnant women (2019) · Cochrane | RR 1.71 [0.48, 6.16] | 5 studies · 338 participants | Very low |
Azithromycin vs doxycycline Adverse events Men · men and non‐pregnant women with symptomatic (uterine cervicitis and urethritis), or asymptomatic genital CT infection,… Antibiotics for treating urogenital Chlamydia trachomatis infection in men and non‐pregnant women (2019) · Cochrane | RR 0.83 [0.67, 1.02] | 6 studies · 1424 participants | Low |
Azithromycin vs doxycycline Adverse events Men and women · men and non‐pregnant women with symptomatic (uterine cervicitis and urethritis), or asymptomatic genital CT infection,… Antibiotics for treating urogenital Chlamydia trachomatis infection in men and non‐pregnant women (2019) · Cochrane | RR 0.83 [0.71, 0.98] | 9 studies · 2261 participants | Moderate |
Azithromycin vs doxycycline Clinical failure Men · men and non‐pregnant women with symptomatic (uterine cervicitis and urethritis), or asymptomatic genital CT infection,… Antibiotics for treating urogenital Chlamydia trachomatis infection in men and non‐pregnant women (2019) · Cochrane | RR 0.94 [0.43, 2.05] | 3 studies · 525 participants | Low |
Azithromycin vs doxycycline Clinical failure Women · men and non‐pregnant women with symptomatic (uterine cervicitis and urethritis), or asymptomatic genital CT infection,… Antibiotics for treating urogenital Chlamydia trachomatis infection in men and non‐pregnant women (2019) · Cochrane | no estimate extracted | NR | No studies |
Azithromycin vs doxycycline Antimicrobial resistance · men and non‐pregnant women with symptomatic (uterine cervicitis and urethritis), or asymptomatic genital CT infection,… Antibiotics for treating urogenital Chlamydia trachomatis infection in men and non‐pregnant women (2019) · Cochrane | no estimate extracted | NR | No studies |
Azithromycin vs doxycycline Reinfection · men and non‐pregnant women with symptomatic (uterine cervicitis and urethritis), or asymptomatic genital CT infection,… Antibiotics for treating urogenital Chlamydia trachomatis infection in men and non‐pregnant women (2019) · Cochrane | no estimate extracted | NR | No studies |
Doxycycline vs quinolones Microbiological failure Men Doxycycline 100 mg twice a day for 7 days vs ofloxacin 200 mg‐400 mg once a day for 7 days · men and non‐pregnant women with symptomatic (uterine cervicitis and urethritis), or asymptomatic genital CT infection,… Antibiotics for treating urogenital Chlamydia trachomatis infection in men and non‐pregnant women (2019) · Cochrane | RR 8.53 [0.43, 167.38] | 2 studies · 80 participants | Very low |
Ceftriaxone vs penicillin G Serological cure assessed by decrease in the CSF VDRL titre · people with neurosyphilis Antibiotic therapy for adults with neurosyphilis (2019) · Cochrane | no estimate extracted | 1 study · 36 participants | Very low |
Ceftriaxone vs penicillin G Clinical cure assessed by RPR decrease · people with neurosyphilis Antibiotic therapy for adults with neurosyphilis (2019) · Cochrane | no estimate extracted | 1 study · 36 participants | Very low |